# OmniSeq INSIGHT

Source: https://onco.cc/drugs/omniseq-insight/  
OnCo record `omniseq-insight` (Test). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Labcorp's tissue gene test for solid tumours, covering 523 genes with a 7 to 10 day turnaround and an option to add PD-L1 testing on the same sample.

## Summary

OmniSeq INSIGHT is Labcorp's tissue comprehensive genomic profiling test for solid tumours, with a stated turnaround of 7 to 10 days. It reads the full coding sequence of 523 cancer-related genes for single-nucleotide variants, insertions and deletions, amplifications and translocations, and RNA from 55 genes for fusions and splice variants, and it reports microsatellite instability and tumour mutational burden; Labcorp's assay specifications list homologous recombination deficiency reporting as an option. It can be combined with PD-L1 testing on the same tissue. The clinical test is a laboratory-developed test; Labcorp also offers the assay to drug developers for research and investigational use, and a plasma version, OmniSeq INSIGHT ctDNA, for research use only.

## Fields

- Kind: Test
- Status: established
- Last checked: 2026-11-03
- Also known as: Labcorp OmniSeq INSIGHT; OmniSeq INSIGHT Genomic Profiling Assay
- Tags: test
- Brand: OmniSeq INSIGHT
- Modality: Tissue comprehensive genomic profiling test (DNA and RNA sequencing)
- Mechanism: Sequencing of the full coding sequence of 523 cancer-related genes in tumour DNA, and of 55 genes in tumour RNA for fusions and splice variants, from formalin-fixed tissue.

## Notes

- What a result means: an alteration linked to an approved drug or a trial is listed with it; a sample with too little tumour can fail, which is not a negative result.

## Sources

- Labcorp Oncology: solid tumour testing (OmniSeq INSIGHT): https://www.labcorp.com/oncology/providers/testing-solutions/solid-tumor
- Labcorp: OmniSeq INSIGHT Genomic Profiling assay specifications: https://www.labcorp.com/oncology/biopharma/portfolio/solid-tissue-profiling/omniseq-insight-genomic

## Connected records

- biomarkers: [MSI-high (microsatellite instability by PCR or sequencing)](https://onco.cc/biomarkers/msi-high/), [PD-L1 CPS (combined positive score)](https://onco.cc/biomarkers/pd-l1-cps/), [PD-L1 TPS (tumour proportion score)](https://onco.cc/biomarkers/pd-l1-tps/), [TMB-high (tumour mutational burden >= 10 mutations per megabase)](https://onco.cc/biomarkers/tmb-high/)
- cancers: [Metastatic cancer (cancer that has spread)](https://onco.cc/cancers/metastatic-cancer/)
- technologies: [Comprehensive genomic profiling](https://onco.cc/technologies/cgp/), [Reference laboratories and companion-diagnostic testing](https://onco.cc/technologies/reference-laboratories/)
- companies: [Labcorp](https://onco.cc/companies/labcorp/)
- terms: [Homologous recombination deficiency (HRD)](https://onco.cc/terms/hrd/), [Microsatellite instability (MSI-H) / mismatch repair deficiency (dMMR)](https://onco.cc/terms/msi/), [Next-generation sequencing (NGS)](https://onco.cc/terms/ngs/), [Tumour mutational burden (TMB)](https://onco.cc/terms/tmb/)

---
JSON: https://onco.cc/api/v1/entities/omniseq-insight.json